EC nod for Nucala for children with severe asthma

The European Commission has granted marketing authorization for Nucala (mepolizumab) as an add-on treatment for severe refractory eosinophilic asthma in pediatric patients aged six up to 17 years.

As a result of this licence extension Nucala is now approved for use for severe refractory eosinophilic asthma in both adult and pediatric patients in the 31 European countries covered by the European Medicines Agency, says the drug’s manufacturer, UK pharma major GlaxoSmithKline (LSE: GSK).

Dr Hal Barron, new chief scientific officer and president, pharmaceuticals R&D, GlaxoSmithKline, said: “Asthma is the most common chronic disease in children. The availability of Nucala as the first targeted treatment available for young children with severe asthma, will help provide asthma control for these children and reassurance to their parents.”